{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01026116",
      "orgStudyIdInfo": {
        "id": "SHBCC09007"
      },
      "organization": {
        "fullName": "Fudan University",
        "class": "OTHER"
      },
      "briefTitle": "A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old",
      "officialTitle": "Comparing EC-wP Versus EP-wP as Adjuvant Therapy for Breast Cancer Patients Less Than 40 Years Old"
    },
    "statusModule": {
      "statusVerifiedDate": "2020-05",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2009-12"
      },
      "primaryCompletionDateStruct": {
        "date": "2016-01",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2016-12-23",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2009-12-03",
      "studyFirstSubmitQcDate": "2009-12-03",
      "studyFirstPostDateStruct": {
        "date": "2009-12-04",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2020-05-09",
      "lastUpdatePostDateStruct": {
        "date": "2020-05-12",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Zhimin Shao",
        "investigatorTitle": "Director of Breast Surgery Department",
        "investigatorAffiliation": "Fudan University"
      },
      "leadSponsor": {
        "name": "Fudan University",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients."
    },
    "conditionsModule": {
      "conditions": [
        "Breast Neoplasms"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 521,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "EC-wP",
          "type": "ACTIVE_COMPARATOR",
          "description": "epirubicin/cyclophosphamide followed weekly paclitaxel",
          "interventionNames": [
            "Drug: Epirubicin",
            "Drug: Cyclophosphamide",
            "Drug: Paclitaxel"
          ]
        },
        {
          "label": "EP-wP",
          "type": "EXPERIMENTAL",
          "description": "epirubicin/paclitaxel followed by weekly paclitaxel",
          "interventionNames": [
            "Drug: Epirubicin",
            "Drug: Cyclophosphamide",
            "Drug: Paclitaxel"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Epirubicin",
          "description": "75 mg/m2 every-3-week for four cycles",
          "armGroupLabels": [
            "EC-wP",
            "EP-wP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Cyclophosphamide",
          "description": "600 mg/m2 every-3-week for four cycles",
          "armGroupLabels": [
            "EC-wP",
            "EP-wP"
          ]
        },
        {
          "type": "DRUG",
          "name": "Paclitaxel",
          "description": "175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks",
          "armGroupLabels": [
            "EC-wP",
            "EP-wP"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "disease-free survival",
          "timeFrame": "every one year"
        },
        {
          "measure": "menstrual resumption rate",
          "description": "Resumption of menses was defined as at least 2 consecutive menstruations, or at least 1 menstruation with a confirmed premenopausal level of FSH and estradiol after chemotherapy",
          "timeFrame": "12 months after chemotherapy"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "overall survival",
          "timeFrame": "every one year"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients, age 18\\~40\n* Unilateral, operable, histologically confirmed adenocarcinoma of the breast\n* Stage I-III\n* Primary surgery with clear margins plus axillary dissection\n* Able to start protocol Rx within 8 weeks of surgery\n* Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer: the immunohistochemical cut-off for ER positive status was\n\n  1% or more staining in nuclei\n* HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by chemotherapy\n* pathologically confirmed regional node-positive disease, or node-negative disease with high-risk factors (primary tumor diameter \\>10 mm when histological grade III, or tumor diameter \\>20 mm when histological grade II)\n* ECOG performance status 0-1\n* Adequate cardiac, renal, hepatic and hematologic function\n\nExclusion Criteria:\n\n* Metastatic disease\n* Bilateral breast cancer (synchronous or metachronous)\n* Prior radiation therapy, hormonal therapy and chemotherapy for breast cancer\n* Previous cancer (except treated basal cell and squamous cell carcinoma of the skin or cancer of the uterine cervix)\n* HER-2 positive (IHC 3+ OR FISH+) and or triple-negative breast cancer\n* Documented history of cardiac disease contradiction anthracyclines\n* Concurrent serious illness\n* Peripheral neuropathy of CTC grade\\>1\n* History of hypersensitivity to drugs formulated in Cremophor EL polyoxyethylated castor oil), the vehicle used for commercial paclitaxel formulations\n* Pregnancy or lactation",
      "healthyVolunteers": false,
      "sex": "FEMALE",
      "minimumAge": "18 Years",
      "maximumAge": "40 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Zhimin Shao",
          "affiliation": "Cancer Hospital, Fudan University",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Department of Breast Surgery, Cancer Hospital, Fudan University",
          "city": "Shanghai",
          "zip": "200032",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "33822134",
          "type": "DERIVED",
          "citation": "Yu KD, Ge JY, Liu XY, Mo M, He M, Shao ZM; SPECTRUM Investigators. Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial. J Natl Cancer Inst. 2021 Oct 1;113(10):1352-1359. doi: 10.1093/jnci/djab065."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-09-08"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D001943",
          "term": "Breast Neoplasms"
        }
      ],
      "ancestors": [
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D001941",
          "term": "Breast Diseases"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D015251",
          "term": "Epirubicin"
        },
        {
          "id": "D003520",
          "term": "Cyclophosphamide"
        },
        {
          "id": "D017239",
          "term": "Paclitaxel"
        }
      ],
      "ancestors": [
        {
          "id": "D004317",
          "term": "Doxorubicin"
        },
        {
          "id": "D003630",
          "term": "Daunorubicin"
        },
        {
          "id": "D018943",
          "term": "Anthracyclines"
        },
        {
          "id": "D009279",
          "term": "Naphthacenes"
        },
        {
          "id": "D011084",
          "term": "Polycyclic Aromatic Hydrocarbons"
        },
        {
          "id": "D006841",
          "term": "Hydrocarbons, Aromatic"
        },
        {
          "id": "D006844",
          "term": "Hydrocarbons, Cyclic"
        },
        {
          "id": "D006838",
          "term": "Hydrocarbons"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        },
        {
          "id": "D011083",
          "term": "Polycyclic Compounds"
        },
        {
          "id": "D000617",
          "term": "Aminoglycosides"
        },
        {
          "id": "D006027",
          "term": "Glycosides"
        },
        {
          "id": "D002241",
          "term": "Carbohydrates"
        },
        {
          "id": "D010752",
          "term": "Phosphoramide Mustards"
        },
        {
          "id": "D009588",
          "term": "Nitrogen Mustard Compounds"
        },
        {
          "id": "D009150",
          "term": "Mustard Compounds"
        },
        {
          "id": "D006846",
          "term": "Hydrocarbons, Halogenated"
        },
        {
          "id": "D063088",
          "term": "Phosphoramides"
        },
        {
          "id": "D009943",
          "term": "Organophosphorus Compounds"
        },
        {
          "id": "D043823",
          "term": "Taxoids"
        },
        {
          "id": "D043822",
          "term": "Cyclodecanes"
        },
        {
          "id": "D003516",
          "term": "Cycloparaffins"
        },
        {
          "id": "D006840",
          "term": "Hydrocarbons, Alicyclic"
        },
        {
          "id": "D004224",
          "term": "Diterpenes"
        },
        {
          "id": "D013729",
          "term": "Terpenes"
        }
      ]
    }
  },
  "hasResults": false,
  "McodeResults": {
    "extracted_entities": [],
    "mcode_mappings": [
      {
        "resourceType": "Condition",
        "mcode_element": "CancerCondition",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancercondition",
          "display": "CancerCondition"
        },
        "value": "Breast Neoplasms",
        "mapping_confidence": 1.0,
        "source_text_fragment": "Conditions: Breast Neoplasms",
        "mapping_rationale": "Direct statement of cancer condition using standard oncology terminology",
        "id": "6539ebc7-e3db-4ff2-8370-dd724b3311c7"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "PatientSex",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "patientsex",
          "display": "PatientSex"
        },
        "value": "Female",
        "mapping_confidence": 1.0,
        "source_text_fragment": "Female patients, age 18~40",
        "mapping_rationale": "Explicitly states female patients",
        "id": "3535e7da-88a8-475f-a2af-3f311cb49f5f"
      },
      {
        "resourceType": "Condition",
        "mcode_element": "CancerCondition",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancercondition",
          "display": "CancerCondition"
        },
        "value": "Adenocarcinoma of breast",
        "mapping_confidence": 1.0,
        "source_text_fragment": "histologically confirmed adenocarcinoma of the breast",
        "mapping_rationale": "Explicit diagnosis of breast adenocarcinoma",
        "id": "b26f99dc-9a73-4055-8111-7269bfaccd60"
      },
      {
        "resourceType": "Condition",
        "mcode_element": "CancerCondition",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancercondition",
          "display": "CancerCondition"
        },
        "value": "ER+ breast cancer",
        "mapping_confidence": 1.0,
        "source_text_fragment": "estrogen-receptor positive (ER+) breast cancer",
        "mapping_rationale": "Explicit ER+ status confirmation",
        "id": "28bd1f2d-7b62-4535-b4d5-cb5f6dfd5a60"
      },
      {
        "resourceType": "Condition",
        "mcode_element": "CancerCondition",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancercondition",
          "display": "CancerCondition"
        },
        "value": "HER-2 negative",
        "mapping_confidence": 1.0,
        "source_text_fragment": "HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test",
        "mapping_rationale": "Explicit HER-2 negative status",
        "id": "ee66a1a1-4151-48c3-b0e3-c511be6c7485"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "TNMStage",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "tnmstage",
          "display": "TNMStage"
        },
        "value": "Stage I-III",
        "mapping_confidence": 1.0,
        "source_text_fragment": "Stage I-III",
        "mapping_rationale": "Explicit cancer stage range",
        "id": "c923fbbe-f395-4357-b631-3fb8fe762bf0"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "TumorSize",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "tumorsize",
          "display": "TumorSize"
        },
        "value": ">10 mm or >20 mm",
        "mapping_confidence": 0.9,
        "source_text_fragment": "primary tumor diameter >10 mm when histological grade III, or tumor diameter >20 mm when histological grade II",
        "mapping_rationale": "Explicit tumor size criteria for high-risk factors",
        "id": "917378bd-fab2-425a-b83c-07f2abfb249c"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "LymphNodeInvolvement",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "lymphnodeinvolvement",
          "display": "LymphNodeInvolvement"
        },
        "value": "Node-positive or node-negative with high-risk factors",
        "mapping_confidence": 1.0,
        "source_text_fragment": "pathologically confirmed regional node-positive disease, or node-negative disease with high-risk factors",
        "mapping_rationale": "Explicit lymph node status criteria",
        "id": "c0ce691f-4360-4860-9065-2b847c54f636"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "CancerTreatment",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancertreatment",
          "display": "CancerTreatment"
        },
        "value": "Primary surgery with clear margins plus axillary dissection",
        "mapping_confidence": 1.0,
        "source_text_fragment": "Primary surgery with clear margins plus axillary dissection",
        "mapping_rationale": "Explicit surgical treatment description",
        "id": "a43419af-78c1-43dc-b5eb-8a4db945dfef"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "CancerTreatment",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancertreatment",
          "display": "CancerTreatment"
        },
        "value": "Chemotherapy",
        "mapping_confidence": 0.8,
        "source_text_fragment": "negative in situ hybridization test by chemotherapy",
        "mapping_rationale": "Mentions chemotherapy in context of HER2 testing",
        "id": "c8f666cf-2207-4ae8-910b-889906eda2fc"
      },
      {
        "resourceType": "Condition",
        "mcode_element": "CancerCondition",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancercondition",
          "display": "CancerCondition"
        },
        "value": "breast cancer",
        "mapping_confidence": 1.0,
        "source_text_fragment": "young breast cancer patients are characterized by aggressive clinical history",
        "mapping_rationale": "Direct mention of breast cancer diagnosis",
        "id": "99a2d9ca-5659-4f8a-a91e-2054da4ea3ae"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "PatientAgeGroup",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "patientagegroup",
          "display": "PatientAgeGroup"
        },
        "value": "young",
        "mapping_confidence": 0.9,
        "source_text_fragment": "young breast cancer patients are characterized by aggressive clinical history",
        "mapping_rationale": "Explicit mention of young patient population",
        "id": "cba180af-ca46-4815-9099-72cc4dc0b1bd"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "CancerTreatment",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancertreatment",
          "display": "CancerTreatment"
        },
        "value": "paclitaxel",
        "mapping_confidence": 1.0,
        "source_text_fragment": "different strategies incorporating paclitaxel to anthracycline-based regimens",
        "mapping_rationale": "Direct mention of paclitaxel as part of treatment regimen",
        "id": "9bc387d8-436f-4c8f-b601-8ca83b9f9e9f"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "CancerTreatment",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancertreatment",
          "display": "CancerTreatment"
        },
        "value": "anthracycline-based regimens",
        "mapping_confidence": 1.0,
        "source_text_fragment": "different strategies incorporating paclitaxel to anthracycline-based regimens",
        "mapping_rationale": "Direct mention of anthracycline-based treatment regimens",
        "id": "7d1a3c8b-0e61-4850-b37d-c79abdb454aa"
      },
      {
        "resourceType": "Condition",
        "mcode_element": "CancerCondition",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancercondition",
          "display": "CancerCondition"
        },
        "value": "Breast Cancer",
        "mapping_confidence": 1.0,
        "source_text_fragment": "Adjuvant Therapy for Operable Breast Cancer Patients",
        "mapping_rationale": "Direct mention of breast cancer in clinical context",
        "id": "01e5c842-dc59-425a-97f1-1112858708af"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "Age",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "age",
          "display": "Age"
        },
        "value": "Less Than 40 Years Old",
        "mapping_confidence": 1.0,
        "source_text_fragment": "Patients Less Than 40 Years Old",
        "mapping_rationale": "Explicit age range specification for patient population",
        "id": "56356204-2897-4c45-85ae-b6776d1ac31c"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "CancerTreatment",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancertreatment",
          "display": "CancerTreatment"
        },
        "value": "EC-wP",
        "mapping_confidence": 0.9,
        "source_text_fragment": "Comparing EC-wP Versus EP-wP as Adjuvant Therapy",
        "mapping_rationale": "EC-wP is a recognized chemotherapy regimen for breast cancer",
        "id": "aa9e6f16-f1b8-4626-b220-6185996f977e"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "CancerTreatment",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancertreatment",
          "display": "CancerTreatment"
        },
        "value": "EP-wP",
        "mapping_confidence": 0.9,
        "source_text_fragment": "Comparing EC-wP Versus EP-wP as Adjuvant Therapy",
        "mapping_rationale": "EP-wP is a recognized chemotherapy regimen for breast cancer",
        "id": "cf22cb49-455c-4ff0-b322-8243d6134b38"
      },
      {
        "resourceType": "Observation",
        "mcode_element": "CancerConditionStatus",
        "code": {
          "system": "http://hl7.org/fhir/us/mCODE",
          "code": "cancerconditionstatus",
          "display": "CancerConditionStatus"
        },
        "value": "Operable",
        "mapping_confidence": 1.0,
        "source_text_fragment": "Operable Breast Cancer Patients",
        "mapping_rationale": "Direct statement that patients have operable breast cancer",
        "id": "1f5a99ac-370a-4c23-a715-7315e31163a0"
      }
    ],
    "source_references": [],
    "validation": {
      "valid": true,
      "errors": [],
      "warnings": [],
      "compliance_score": 1.0
    },
    "metadata": {
      "pipeline_version": "Mcode_pipeline_v1",
      "engine_type": "LLM",
      "entities_count": 0,
      "mapped_count": 19,
      "compliance_score": 1.0,
      "token_usage": {
        "prompt_tokens": 829,
        "completion_tokens": 650,
        "total_tokens": 1479
      },
      "aggregate_token_usage": {
        "prompt_tokens": 0,
        "completion_tokens": 0,
        "total_tokens": 0,
        "model_name": "",
        "provider_name": ""
      }
    },
    "error": null
  }
}